Mutations underlying Episodic Ataxia type-1 antagonize Kv1.1 RNA editing

dc.contributor.author Ferrick-Kiddie, Elizabeth A.
dc.contributor.author Rosenthal, Joshua J. C.
dc.contributor.author Ayers, Gregory D.
dc.contributor.author Emeson, Ronald B.
dc.date.accessioned 2017-03-01T16:06:51Z
dc.date.available 2017-03-01T16:06:51Z
dc.date.issued 2017-02-20
dc.description © The Author(s), 2017. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Scientific Reports 7 (2017): 41095, doi:10.1038/srep41095. en_US
dc.description.abstract Adenosine-to-inosine RNA editing in transcripts encoding the voltage-gated potassium channel Kv1.1 converts an isoleucine to valine codon for amino acid 400, speeding channel recovery from inactivation. Numerous Kv1.1 mutations have been associated with the human disorder Episodic Ataxia Type-1 (EA1), characterized by stress-induced ataxia, myokymia, and increased prevalence of seizures. Three EA1 mutations, V404I, I407M, and V408A, are located within the RNA duplex structure required for RNA editing. Each mutation decreased RNA editing both in vitro and using an in vivo mouse model bearing the V408A allele. Editing of transcripts encoding mutant channels affects numerous biophysical properties including channel opening, closing, and inactivation. Thus EA1 symptoms could be influenced not only by the direct effects of the mutations on channel properties, but also by their influence on RNA editing. These studies provide the first evidence that mutations associated with human genetic disorders can affect cis-regulatory elements to alter RNA editing. en_US
dc.description.sponsorship This work was supported by the Vanderbilt Molecular Endocrinology Training Program (T32DK007563; E.A.F.K.), a Ruth L. Kirschstein National Research Service Award (F31NS087911; E.A.F.K), a Vanderbilt Dissertation Enhancement Grant (E.A.F.K.), and the Vanderbilt Joel G. Hardman Chair in Pharmacology (R.B.E). Additional support for J.J.C.R. included NINDS (R0111223855, R01NS64259) and the Cystic Fibrosis Foundation Therapeutics (Rosent14XXO). Infrastructural support for J.J.C.R. was provided by NIGMS (P20GM103642), NIMH (G12-MD007600), and NSF (DBI 0115825, DBI 1337284). en_US
dc.identifier.citation Scientific Reports 7 (2017): 41095 en_US
dc.identifier.doi 10.1038/srep41095
dc.identifier.uri https://hdl.handle.net/1912/8757
dc.language.iso en_US en_US
dc.publisher Nature Publishing Group en_US
dc.relation.uri https://doi.org/10.1038/srep41095
dc.rights Attribution 4.0 International *
dc.rights.uri http://creativecommons.org/licenses/by/4.0/ *
dc.title Mutations underlying Episodic Ataxia type-1 antagonize Kv1.1 RNA editing en_US
dc.type Article en_US
dspace.entity.type Publication
relation.isAuthorOfPublication 20a0aece-2258-4b62-b6e7-1e1074cbae96
relation.isAuthorOfPublication aaf34567-dcfe-465a-9ccb-c11a63ab61d0
relation.isAuthorOfPublication d609155b-6c54-429f-a762-4ae274178f0b
relation.isAuthorOfPublication e3aa50a3-2172-4ac2-953a-d7a8f2f39072
relation.isAuthorOfPublication.latestForDiscovery 20a0aece-2258-4b62-b6e7-1e1074cbae96
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
srep41095.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Description:
Article
Thumbnail Image
Name:
srep41095-s1.pdf
Size:
1.03 MB
Format:
Adobe Portable Document Format
Description:
Supplementary Figures
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.89 KB
Format:
Item-specific license agreed upon to submission
Description: